BRAIN CANCER

FDA designates AMXT 1501 and DFMO as an orphan drug for neuroblastoma, aiming to enhance treatment outcomes for pediatric patients.

Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent patient needs.

The FDA approves selumetinib for young patients with neurofibromatosis type 1, offering hope for effective treatment of inoperable tumors.

FDA grants orphan drug designation to BA-101, a promising treatment for glioblastoma, aiming to improve outcomes in this challenging cancer.

Lantern Pharma advances pediatric CNS cancer treatment with FDA guidance on LP-184 trial, targeting rare tumors and enhancing therapy with spironolactone.

In a pilot study, a novel regimen showed 100% disease control in 5 patients with recurrent GBM, with 2 achieving near complete response.

Dordaviprone received accelerated FDA approval for H3 K27M-mutant diffuse midline glioma, an aggressive brain tumor, making it the first approved systemic therapy for this rare disease.

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this aggressive brain cancer.

FDA accelerates approval of dordaviprone, the first targeted therapy for aggressive diffuse midline glioma, offering hope for patients with H3 K27M mutation.

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor cells.

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, offering hope for patients with limited options.

Researchers explore glioblastoma's genetic complexity using innovative spatial profiling, aiming to enhance treatment strategies and understand tumor resistance.

The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing difficulties.

FDA designates MB-101 CAR T-cell therapy for glioblastoma, highlighting its potential in treating aggressive brain tumors with innovative combination strategies.

A new trial optimizes rhenium Re 186 obisbemeda dosing for treating leptomeningeal metastases, aiming to enhance safety and efficacy in CNS cancer therapy.

The SonoClear System revolutionizes neurosurgery with FDA breakthrough designation, enhancing ultrasound imaging for safer tumor resections in glioma surgeries.

Myrio's PHOX2B PC-CAR T therapy gains FDA approval for human trials, promising innovative treatment for patients with high-risk neuroblastoma.

BCB-276 has earned regenerative medicine advanced therapy designation from the FDA in diffuse intrinsic pontine glioma, an incurable pediatric tumor.

The anti-GD2 therapy naxitamab has been included in the NCCN Clinical Practice Guidelines in Oncology for the treatment of patients with neuroblastoma.

The FDA requires more data to approve the application of TLX101-CDx for the detection and differentiation of glioma.

FDA designates BCB-276 as a breakthrough therapy for pediatric DIPG, offering hope for improved treatment of this challenging brain tumor.

Preliminary results from the phase 2 IPAX-Linz study show encouraging efficacy and a favorable safety profile for TLX101 in recurrent high-grade glioma.

A pilot study will evaluate Alpha DaRT for the treatment of patients with recurrent glioblastoma.

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with glioblastoma.